Search Results

You are looking at 11 - 20 of 109 items for :

  • "cardiac hypertrophy" x
  • All content x
Clear All
Free access

Wu Luo, Lan Huang, Jingying Wang, Fei Zhuang, Zheng Xu, Haimin Yin, Yuanyuan Qian, Guang Liang, Chao Zheng, and Yi Wang

panels B, C, and D; n  = 7; Treatment groups are as shown in Fig. 1; * P  < 0.05, ** P  < 0.01 compared to Ctrl; # P  < 0.05, ## P  < 0.01 compared to T1DM alone. To supplement our studies, we measured markers of cardiac hypertrophy, alpha

Free access

Chun-Hsien Chu, Bor-Show Tzang, Li-Mien Chen, Chia-Hua Kuo, Yi-Chang Cheng, Ling-Yun Chen, Fuu-Jen Tsai, Chang-Hai Tsai, Wei-Wen Kuo, and Chih-Yang Huang

Introduction Cardiac hypertrophy can roughly be divided into two types: physiological and pathological ( Hunter & Chien 1999 ). In shorter stresses, physiological hypertrophy is an adaptive response to maintain heart function by increasing the size

Free access

Pongpan Tanajak, Siriporn C Chattipakorn, and Nipon Chattipakorn

cascade ( Joki et al . 2015 ). Recent studies found that FGF21 protects against isoproterenol (ISO) induced cardiac hypertrophy by activating anti-oxidative pathways ( Planavila et al . 2013 , 2014 ) and promoting FAO ( Planavila et al . 2013 ). FGF21

Free access

Sangeeta Maity, Dipak Kar, Kakali De, Vivek Chander, and Arun Bandyopadhyay

, dysfunction ultimately leading to heart failure. Cardiac hypertrophy ensuing hyperthyroidism is due to the hyper-dynamic circulatory system that results from an enhanced metabolic rate, increased blood volume, and decreased peripheral resistance, and all these

Free access

Francisco Altamirano, César Oyarce, Patricio Silva, Marcela Toyos, Carlos Wilson, Sergio Lavandero, Per Uhlén, and Manuel Estrada

muscle mass ( Evans 2004 ). Exogenously administrated, elevated testosterone concentrations induce cardiac hypertrophy in vitro ( Marsh et al . 1998 ) and in vivo ( Cabral et al . 1988 , Malhotra et al . 1990 , Nahrendorf et al . 2003 ), but the

Free access

Fausto Bogazzi, Francesco Raggi, Federica Ultimieri, Dania Russo, Antonella Manariti, Aldo D’Alessio, Paolo Viacava, Giovanni Fanelli, Maurizio Gasperi, Luigi Bartalena, and Enio Martino

Introduction Cardiac hypertrophy is a common finding of systemic manifestations of growth hormone/insulin-like growth factor-I (GH/IGF-1) excess in acromegalic patients ( Lie & Grossman 1980 , Saccà et al. 1994 , Melmed 2006

Free access

Chiung-Kuei Huang, Soo Ok Lee, Eugene Chang, Haiyan Pang, and Chawnshang Chang

cardiac hypertrophy Cardiac hypertrophy is prevalent in a substantial portion of individuals with hypertension ( Devereux et al . 1987 , Kaplinsky 1994 ) and recognized as an independent risk factor for congestive heart failure and sudden cardiac death

Free access

Sheng-Gao Tang, Xiao-Yu Liu, Ji-Ming Ye, Ting-Ting Hu, Ying-Ying Yang, Ting Han, and Wen Tan

normal saline solvent) was 8 mg/kg/day (twice daily), which optimized by our researches about STVNa on pressure overload induced cardiac hypertrophy (unpublished) and doses previously shown to be neuroprotective in rats ( Hu et al . 2016 ). Additionally

Free access

Kook Hwan Kim and Myung-Shik Lee

another study showed FGF21 induction in the liver and adipose tissue but not in the ischemic myocardium of mice ( Liu et al . 2013 ). Importantly, stress-induced cardiac hypertrophy was increased in Fgf21 − / − mice, while exogenous FGF21 administration

Free access

Beatriz S Amorim, Cintia B Ueta, Beatriz C G Freitas, Renata J Nassif, Cecília Helena de Azevedo Gouveia, Marcelo A Christoffolete, Anselmo S Moriscot, Carmen Lucia Lancelloti, Flávia Llimona, Hermes Vieira Barbeiro, Heraldo Possolo de Souza, Sergio Catanozi, Marisa Passarelli, Marcelo S Aoki, Antonio C Bianco, and Miriam O Ribeiro

%), had less total fat content (−∼70%), less total body water (∼15%; Table 2 ), while at the same time exhibited cardiac hypertrophy (∼23%; Table 1 ). Figure 1 Effects of GC-24 on body weight and composition. Rats were placed on a high-fat diet for 4